CD40LG and leprosy: Based on these findings, we recommend the following: routine anti‐PGL‐I IgM screening of blood donors in leprosy‐endemic regions to identify individuals at risk of subclinical or early‐stage disease; comprehensive clinical evaluation (including qPCR and ultrasound) for individuals with high anti‐PGL‐I IgM titres, followed by appropriate treatment and contact tracing; Surveillance studies to assess the potential for M. leprae transmission through blood donation and to inform transfusion safety policies in endemic and emerging areas.